Alzheimer’s is a devastatingly progressive disease that robs our loved ones of their memories and personalities. Presently 5.7 million Americans are living with Alzheimer’s. By 2050, this number is projected to rise to nearly 14 million. Early and accurate diagnosis could save up to $7.9 trillion in medical and care costs, according to the Alzheimer’s Association. There is increasing evidence that Alzheimer’s disease lies on a continuum with dynamic neurobiological and pathological symptoms. As the disease progresses, targeting specific therapeutic windows for intervention may give patients

Alzheimer’s is a devastatingly progressive disease that robs our loved ones of their memories and personalities. Presently 5.7 million Americans are living with Alzheimer’s. By 2050, this number is projected to rise to nearly 14 million. Early and accurate diagnosis could save up to $7.9 trillion in medical and care costs, according to the Alzheimer’s Association. There is increasing evidence that Alzheimer’s disease lies on a continuum with dynamic neurobiological and pathological symptoms. As the disease progresses, targeting specific therapeutic windows for intervention may give patients

Alzheimer’s disease could affect more than 14 million Americans by 2050 if a cure isn’t found, the Alzheimer’s Association reports. The Center for Alzheimer’s Disease and Related Disorders, part of SIU Medicine’s Neuroscience Institute, is hoping new research studies might change that. Three clinical trials, including the Aware Study by AbbVie, Tauriel Study by Genentech, and GRADUATE I Study by Roche, are now recruiting participants with memory impairment or probable mild-to-moderate Alzheimer’s disease. The goal of these studies is test how well the medical treatments work at slowing the

Alzheimer’s disease could affect more than 14 million Americans by 2050 if a cure isn’t found, the Alzheimer’s Association reports. The Center for Alzheimer’s Disease and Related Disorders, part of SIU Medicine’s Neuroscience Institute, is hoping new research studies might change that. Three clinical trials, including the Aware Study by AbbVie, Tauriel Study by Genentech, and GRADUATE I Study by Roche, are now recruiting participants with memory impairment or probable mild-to-moderate Alzheimer’s disease. The goal of these studies is test how well the medical treatments work at slowing the

SIU Medicine audiologist Jennifer L. Berry, AuD, CCC-A, took the title "Best Audiologist" in the Illinois Times' 2018 Best of Springfield awards. Hundreds of readers took to the internet to cast their votes for their favorite restaurants, health care providers, dry cleaners and more in the annual contest. Berry specializes in treating hearing loss and tinnitus and provides cochlear implant services, hearing screenings and hearing aid services. She joined SIU Medicine's Department of Surgery after spending several years researching hearing loss and tinnitus. Berry sees patients at the Ear Nose

SIU Medicine audiologist Jennifer L. Berry, AuD, CCC-A, took the title "Best Audiologist" in the Illinois Times' 2018 Best of Springfield awards. Hundreds of readers took to the internet to cast their votes for their favorite restaurants, health care providers, dry cleaners and more in the annual contest. Berry specializes in treating hearing loss and tinnitus and provides cochlear implant services, hearing screenings and hearing aid services. She joined SIU Medicine's Department of Surgery after spending several years researching hearing loss and tinnitus. Berry sees patients at the Ear Nose